XML 64 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Exclusive License and Option to Acquire Fortis Therapeutics - Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets (Details) - USD ($)
$ in Thousands
May 05, 2023
Jun. 30, 2023
Dec. 31, 2022
Liabilities      
Nonredeemable non-controlling interests   $ 20,487 $ 19,967
Fortis Therapeutics [Member]      
Business Acquisition [Line Items]      
Purchase consideration $ 0    
Assets      
Cash and cash equivalents 656    
Prepaid expenses and other current assets 82    
IPR&D assets 24,400    
Total assets 25,138    
Liabilities      
Accounts payable 2,671    
Accrued and other current liabilities 703    
Total liabilities 3,374    
Redeemable non-controlling interests 21,480    
Nonredeemable non-controlling interests 520    
Net identifiable assets, liabilities and non-controlling interests (236)    
Loss on asset acquisition $ (236)